N Engl J Med 383(15):14131424 Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Verma S, Lapuerta P, Pitt B (2021) SOLOIST-WHF Trial Investigators
Glugacon-like peptide-2: Broad receptor expression, limited therapeutic effect on intestinal inflammation and novel role in liver regeneration
Full therapeutic benefit is typically observed only after reaching the target maintenance dose through gradual titration over several weeks or months
While we dont know which patients will gain weight back if they stop the medications (or cede back other benefits), its perfectly reasonable to sort that out by giving all patients a chance to stop taking the medication, once they have reached their health goals